What medication should be given to treat neuroleptic malignant syndrome in an adult patient who develops fever, tachycardia, irritability, and tremor while taking olanzapine and metoclopramide (Reglan)?

Immediate Treatment: Benzodiazepines for Neuroleptic Malignant Syndrome

This patient has neuroleptic malignant syndrome (NMS) from the combination of olanzapine and metoclopramide, and benzodiazepines (lorazepam or midazolam) should be the first-line medication for managing agitation and muscle rigidity, along with immediate discontinuation of both offending agents and aggressive supportive care.

Recognition and Immediate Actions

The clinical presentation—fever, tachycardia, irritability, and tremor—in a patient taking two dopamine antagonists (olanzapine and metoclopramide) is highly concerning for NMS. The FDA drug label for Reglan explicitly warns that metoclopramide can cause NMS, characterized by hyperthermia, muscle rigidity, altered consciousness, and autonomic instability 1. Similarly, olanzapine carries this risk 2.

Critical first steps:

• Immediately discontinue both olanzapine and metoclopramide 1
• Assess for the complete NMS tetrad: altered mental status, hyperthermia, muscle rigidity, and autonomic instability 3
• Check creatine kinase, complete blood count, liver enzymes, and electrolytes 3

Primary Pharmacologic Management

Benzodiazepines as First-Line Treatment

For acute symptom control, administer benzodiazepines:

• Lorazepam: 1-2 mg IV/IM initially, can repeat every 1-2 hours as needed 3, 4
• Midazolam: 2.5-5 mg IV/IM for more rapid onset if severe agitation 3

The 2016 Pediatrics guideline emphasizes that benzodiazepines are useful for controlling muscular activity and agitation in NMS 3. A case report demonstrated successful treatment of severe NMS with high-dose lorazepam and diazepam without requiring dantrolene or dopaminergic agents 4.

Rationale: Benzodiazepines address the muscle rigidity and agitation without further antagonizing dopamine receptors, which would worsen NMS.

Adjunctive Pharmacologic Options

Bromocriptine (Dopamine Agonist)

If symptoms persist despite benzodiazepines and supportive care, add bromocriptine:

• Starting dose: 2.5 mg orally 2-3 times daily
• Can titrate up to 10-20 mg three times daily as needed

Multiple case reports demonstrate successful NMS treatment with bromocriptine 5, 6, 7. The drug works by restoring dopaminergic activity that has been blocked by the antipsychotics 3.

Dantrolene: Use With Caution

Dantrolene 1-2.5 mg/kg IV every 6 hours can be considered for severe muscle rigidity, but evidence is mixed:

• The 2016 Pediatrics guideline lists dantrolene as an option for severe cases 3
• However, a 2007 systematic review of 271 cases found that dantrolene monotherapy was associated with higher overall mortality and should not be considered first-line 8
• Dantrolene may be most useful when premedication consisted of neuroleptic monotherapy 8
• Two recent case reports showed successful use of dantrolene for NMS 9, 6

The evidence suggests bromocriptine is preferred over dantrolene as an adjunct to benzodiazepines.

Critical Supportive Care Measures

Beyond pharmacotherapy, aggressive supportive management is essential 1:

1. Cooling measures for hyperthermia (external cooling, not antipyretics—fever is from muscle activity, not hypothalamic dysregulation) 3
2. Aggressive IV hydration with isotonic crystalloids 10
3. Alkalinization of urine if rhabdomyolysis present (myoglobin nephrotoxicity prevention)
4. Continuous cardiac monitoring for dysrhythmias 3
5. ICU-level monitoring for autonomic instability

Medications to Avoid

Do NOT use additional antipsychotics for agitation management, as this will worsen NMS 3. The delirium guidelines listing haloperidol and other antipsychotics 11, 12 are not applicable here—those are for delirium management, not NMS treatment.

Common Pitfalls

• Mistaking NMS for sepsis or other causes of fever: Always obtain history of recent antipsychotic or metoclopramide use 3
• Using succinylcholine for intubation: Risk of severe hyperkalemia from rhabdomyolysis; use non-depolarizing agents like rocuronium or vecuronium instead 3
• Reintroducing the offending agent too soon: Wait at least 2 weeks after complete resolution before considering any antipsychotic 3
• Using indirect sympathomimetics (like dopamine) for blood pressure support: Use direct-acting agents (phenylephrine, norepinephrine) instead 3

Treatment Algorithm Summary

1. Discontinue olanzapine and metoclopramide immediately
2. Start benzodiazepines (lorazepam 1-2 mg IV or midazolam 2.5-5 mg IV)
3. Initiate aggressive supportive care (cooling, hydration, monitoring)
4. If inadequate response after 2-4 hours, add bromocriptine 2.5 mg PO TID
5. Consider dantrolene 1-2.5 mg/kg IV only for severe, refractory muscle rigidity
6. Monitor creatine kinase, renal function, and electrolytes closely

The mortality from NMS has decreased from 76% in the 1960s to less than 10-15% with modern recognition and treatment 3, making early identification and aggressive management critical for survival.